ArticleBlood2018
First-in-human phase 1 clinical study of the IL-15 superagonist complex ALT-803 to treat relapse after transplantation.
Open access · bronzeAbstract readClinical Trial, Phase IMulticenter Study
In one paragraph
Article in Blood, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 270 papers.
0numbers the graph read from it
0cells of the map it votes in
270citing papers in PubMed
19.3field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
270 citing papers in PubMed, 401 citations in OpenAlex.
- Durable responses to triplet immunotherapy targeting TGF-β, PD-L1, and tumor antigen, with an IL-15 receptor superagonist in mismatch repair proficient castration-resistant prostate cancer.Journal for immunotherapy of cancer · 2026Trial
- Trial
- N-803, an IL-15 Superagonist Complex as Maintenance Therapy After Allogeneic Donor Stem Cell Transplant for Acute Myeloid Leukemia or Myelodysplastic Syndrome; A Phase 2 Trial.Transplantation and cellular therapy · 2024Trial
- Advances in natural killer cell immunotherapy for hematologic malignancies.Cancer biology & therapy · 2026Review
- Localized immunotherapy via dissolving microneedles for the prevention of breast cancer recurrence.Drug delivery and translational research · 2026Review
- Host-directed immune therapies: a second front in the battle against sepsis.The Journal of clinical investigation · 2026Review
- Review
- Exercise-mobilized lymphocytes enhance the function of cytokine-induced memory-like NK cells against myeloid leukemia.Blood advances · 2026Article
- Retinoids enhance NK effector function against HIV-infected CD4 T cells.Journal of virology · 2026Article
- Long-acting interleukin-7 improves the efficacy of oncolytic viral therapy in glioblastoma.Nature communications · 2026Article
- Advances in IL-2 Family Cytokine-Based Cancer Therapies: Overcoming Challenges Through Molecular Engineering and Delivery Strategies.Immune network · 2026Review
- Co-delivery of IL-12/IL-15/IL-18 engineered DC vaccines with anti-IL-10R and nanoconjugated methotrexate in melanoma.Frontiers in immunology · 2026Article
- Metabolic licensing and restriction of innate immunity in the tumor microenvironment.Frontiers in immunology · 2026Review
- Advancements in nanomedicines for cancer therapy: targeting molecular signaling pathways, activating immune cells, and using photothermal immunomodulation.Frontiers in bioengineering and biotechnology · 2026Review
- The development of a next generation NK cell engager platform by integrating a potency-reduced IL-15 variant to enhance antitumor activity.Antibody therapeutics · 2026Article
- Harnessing the Power of CAR-NK Cells for Solid Tumors: Challenges, Innovations, and Future Frontiers in Immunotherapy.Cancer communications (London, England) · 2026Review
- TGF-βRII/IL-15 immunotherapeutic complex targets exhausted CD8Journal for immunotherapy of cancer · 2025Article
- The ATR inhibitor tuvusertib (M1774) sensitizes prostate carcinoma to natural killer cell-mediated cytotoxicity, which is further augmented by the IL-15 receptor superagonist N-803.Cancer immunology, immunotherapy : CII · 2025Article
- Lynch Syndrome in Focus: A Multidisciplinary Review of Cancer Risk, Clinical Management, and Special Populations.Cancers · 2025Review
- IL-15 transpresentation by ovarian cancer cells improves CD34Oncoimmunology · 2025Article
210 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
26 authors at 5 institutions in 2 countries.
Rizwan RomeeDivision of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, MO.
Sarah CooleyBlood and Marrow Transplant Program and.
Melissa M Berrien-ElliottDivision of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, MO.ORCID 0000-0002-7319-9159
Peter WesterveltDivision of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, MO.
Michael R VernerisBlood and Marrow Transplant Program and.
John E WagnerBlood and Marrow Transplant Program and.
Daniel J WeisdorfBlood and Marrow Transplant Program and.
Bruce R BlazarBlood and Marrow Transplant Program and.
Celalettin UstunBlood and Marrow Transplant Program and.
Todd E DeForBlood and Marrow Transplant Program and.
Sithara VivekMasonic Cancer Center, University of Minnesota, Minneapolis, MN.
Lindsey PeckDivision of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, MO.
John F DiPersioDivision of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, MO.
Amanda F CashenDivision of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, MO.
Rachel KylloDivision of Dermatology, Department of Medicine, and.
Amy MusiekDivision of Dermatology, Department of Medicine, and.
András SchafferDivision of Dermatology, Department of Medicine, and.
Milan J AnadkatDivision of Dermatology, Department of Medicine, and.
Ilana RosmanDivision of Dermatology, Department of Medicine, and.
Daniel MillerDepartment of Dermatology, University of Minnesota, Minneapolis, MN; and.
Jack O EganAltor BioScience, a Nantworks company, Miramar, FL.
Emily K JengAltor BioScience, a Nantworks company, Miramar, FL.
Amy RockAltor BioScience, a Nantworks company, Miramar, FL.
Hing C WongAltor BioScience, a Nantworks company, Miramar, FL.
Todd A FehnigerDivision of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, MO.ORCID 0000-0002-8705-2887
Jeffrey S MillerBlood and Marrow Transplant Program and.
Washington University in St. Louis · USNHS Blood and Transplant · GBAltor BioScience (United States) · USUniversity of Minnesota · USUniversity of Minnesota Medical Center · US
Funding
Trial Design and Biostatistical Support CoreP01CA065493 · NCI · UNIVERSITY OF MINNESOTA TWIN CITIES · PI John E. Wagner · 1995 to 2026
$48.2MTherapeutic Potential of Adaptive NK Cells in Cancer and TransplantationP01CA111412 · NCI · UNIVERSITY OF MINNESOTA TWIN CITIES · PI MILLER, JEFFREY S. · 2005 to 2025
$38.2MUniversity of Minnesota Clinical and Translational Science Institute (UMN CTSI)UL1TR002494 · NCATS · UNIVERSITY OF MINNESOTA · PI BLAZAR, BRUCE R, WEISDORF, DANIEL J · 2018 to 2022
$34.9MTRANSLATING NK CELL BIOLOGY INTO CLINICAL CANCER IMMUNOTHERAPYR01CA205239 · NCI · WASHINGTON UNIVERSITY · PI FEHNIGER, TODD A · 2017 to 2020
$2.4MMechanisms underlying cytokine-induced memory-like natural killer cell differentiation and maintenance.F32CA200253 · NCI · WASHINGTON UNIVERSITY · PI ELLIOTT, MELISSA BERRIEN · 2015 to 2017
$168kNCATS NIH HHS UL1 TR002494NCI NIH HHS F32 CA200253NCI NIH HHS P01 CA065493NCI NIH HHS P01 CA111412NCI NIH HHS R01 CA205239
Abstract
New therapies for patients with hematologic malignancies who relapse after allogeneic hematopoietic cell transplantation (allo-HCT) are needed. Interleukin 15 (IL-15) is a cytokine that stimulates CD8
Indexed as
Hematopoietic Stem Cell TransplantationAdultAgedAntineoplastic AgentsCD8-Positive T-LymphocytesFemaleHematologic NeoplasmsHumansInterleukin-15Killer Cells, NaturalMaleMiddle AgedNeoplasm Recurrence, LocalProteinsRecombinant Fusion ProteinsYoung AdultALT-803Antineoplastic AgentsInterleukin-15ProteinsRecombinant Fusion Proteins
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.